Corvus Pharma Com (CRVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -62,293 | -50,180 | -9,963 | -5,701 | -27,029 |
| Depreciation Amortization | -1,056 | -834 | -331 | -128 | -743 |
| Accounts receivable | -49 | -44 | -9 | N/A | 562 |
| Accounts payable and accrued liabilities | 1,057 | 348 | -312 | 84 | -451 |
| Other Working Capital | -1,647 | -188 | -326 | 219 | -3,594 |
| Other Operating Activity | 38,564 | 33,939 | 303 | 369 | 7,320 |
| Operating Cash Flow | $-25,424 | $-16,959 | $-10,638 | $-5,157 | $-23,935 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -27,489 | -21,401 | -17,511 | -7 | 15,575 |
| PPE Investments | 5 | N/A | N/A | N/A | -34 |
| Investing Cash Flow | $-27,484 | $-21,401 | $-17,511 | $-7 | $15,541 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 49,028 | 30,420 | 30,370 | N/A | 7,855 |
| Financing Cash Flow | $49,028 | $30,420 | $30,370 | $N/A | $7,855 |
| Beginning Cash Position | 12,620 | 12,620 | 12,620 | 12,620 | 13,159 |
| End Cash Position | 8,740 | 4,680 | 14,841 | 7,456 | 12,620 |
| Net Cash Flow | $-3,880 | $-7,940 | $2,221 | $-5,164 | $-539 |
| Free Cash Flow | |||||
| Operating Cash Flow | -25,424 | -16,959 | -10,638 | -5,157 | -23,935 |
| Capital Expenditure | N/A | N/A | N/A | N/A | -34 |
| Free Cash Flow | -25,424 | -16,959 | -10,638 | -5,157 | -23,969 |